Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Prasugrel to be studied in PCI patients in phase III trial

Oct. 28, 2004

Japanese approval sought for Advate

Oct. 27, 2004

New peptides with thrombin-inhibitory activity designed by Canadian scientists

Oct. 26, 2004

Merck KGaA presents novel factor Xa and factor VIIa inhibitors

Oct. 21, 2004

European approval for Kogenate Bayer with Bio-Set

Oct. 20, 2004

No FDA approval for Exanta

Oct. 14, 2004

MC-45308 demonstrates simultaneous antiplatelet and anticoagulant effects

Oct. 11, 2004

ZymoGenetics licenses rFactor XIII to Novo Nordisk

Oct. 7, 2004

BMS scientists present two novel series of factor VIIa inhibitors

Oct. 6, 2004

BioInvent and ThromboGenics to develop treatments for vascular indications

Oct. 4, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...